On Thursday, June 10, the German newspaper “Handelsblatt” reported online and in its print version on the planned IPO of ATAI Life Sciences, a German company specializing in psychedelic drugs. Previously labeled as narcotic drugs, ATAI Life Sciences’ psychedelic-based medications could soon be used to treat depression and anxiety.
“What sounds outlandish to many is seen by investors and medical professionals as an opportunity for shareholders and patients.. […] “These substances have long been taboo in research. That is now changing,” says Mathias Schott of Munich-based financing specialist FCF. He trusts Angermayer to convince investors of the opportunities with his commitment. Like Tesla founder Elon Musk, the German is prepared to promote his investments strongly in public.”
For the Handelsblatt article (in German), please click here.
ABOUT FCF FOX CORPORATE FINANCE
FCF is a specialized Investment Bank and Financing Specialist, advising public and private small/mid-market companies in the German speaking regions.FCF focuses on four primary client segments:
- MidCap: Medium-sized companies with sustainable business models in typical “Mittelstand” industries, such as industrial products and machinery, automotive, communications, logistics, and consumer products
- SmallCap / Growth: Companies with revenues between €20 and €100 million and high / above average growth rates
- DeepTech: R&D-driven companies in technology sectors, entering the commercialization stage with initial fast-growing revenues
- Life Sciences: Highly innovative companies focusing on the development of cutting-edge biotechnology, med-tech, health-tech and pharmaceuticals solutions
FCF structures, arranges and places equity and debt capital transactions and supports its clients’ growth, IPO/Pre-IPO, acquisition and standard balance sheet (re-)financing strategies.
Founded in 2005 and headquartered in Munich, FCF has direct relationships and works with all leading German, European and international financiers, lenders and investment houses addressing German small/mid-cap companies.